Story
Biohaven Stock Jumps 7% on $795 Million Epilepsy Drug Deal with SK Biopharmaceuticals

Biohaven Ltd. (NYSE:BHVN) shares rose 7% on Wednesday following the announcement of a strategic global licensing agreement with SK Biopharmaceuticals for its Kv7 ion channel platform. The deal, centered on the epilepsy treatment candidate opakalim, provides Biohaven with significant upfront capital and potential future payments.
Deal Highlights
Under the terms of the agreement, SK Biopharmaceuticals will make substantial payments to Biohaven, which will de-risk the development program for the smaller biotech firm. The key financial components of the deal include:
- Total Potential Value: Up to $795 million in upfront and milestone payments related to the Kv7 platform.
- Upfront Cash: Biohaven will receive $400 million in cash, consisting of $350 million at closing and an additional $50 million in 2027.
- Future Milestones: The company is eligible for an additional $150 million tied to development and regulatory milestones.
- Royalties: Biohaven will earn tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim, plus royalties on global net sales.
SK Biopharmaceuticals will assume responsibility for all future Kv7 program costs, including certain specified obligations totaling $245 million, according to the announcement.
Strategic Rationale
AdThe partnership leverages the strengths of both companies. SK Biopharmaceuticals gains a late-stage asset that complements its existing commercial footprint in the epilepsy market, where it already sells XCOPRI for partial-onset seizures through a commercial team of over 150 professionals in the U.S.
For Biohaven, the agreement provides a significant infusion of non-dilutive capital while transferring the financial risk of future clinical development and commercialization to its partner. The lead candidate from the platform, opakalim, is a selective Kv7.2/7.3 potassium channel activator currently in a Phase 2/3 trial for focal epilepsy.
Next Steps and Market Impact
Investors reacted positively to the deal's financial structure and strategic fit, driving Biohaven's stock higher. The next major catalyst for the program will be topline results from the RISE3 trial, which are expected in the second half of 2026.
The closing of the transaction is subject to customary conditions, including completion of review under the Hart-Scott-Rodino Antitrust Improvements Act in the U.S.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.